References
- Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol. 1992;12(12):5447–5454.
- Ponting CP, Aravind L. PAS: a multifunctional domain family comes to light. Curr biol: CB. 1997;7(11):R674-R677.
- Weidemann A, Johnson RS. Biology of HIF-1α. Cell Death Differ. 2008;15(4):621–627.
- Ke Q, Costa M. Hypoxia-inducible factor-1 (HIF-1). Mol Pharmacol. 2006;70(5):1469–1480.
- Loboda A, Jozkowicz A, Dulak J. HIF-1 and HIF-2 transcription factors–similar but not identical. Mol Cells. 2010. DOI:https://doi.org/10.1007/s10059-010-0067-2
- Yang SL, Wu C, Xiong ZF, et al. Progress on hypoxia-inducible factor-3: its structure, gene regulation and biological function (Review). Mol Med Rep. 2015. DOI:https://doi.org/10.3892/mmr.2015.3689
- Dales JP, Beaufils N, Silvy M, et al. Hypoxia inducible factor 1α gene (HIF-1α) splice variants: potential prognostic biomarkers in breast cancer. BMC Med. 2010;8(1). DOI:https://doi.org/10.1186/1741-7015-8-44
- Tolonen JP, Heikkilä M, Malinen M, et al. A long hypoxia-inducible factor 3 isoform 2 is a transcription activator that regulates erythropoietin. Cell Mol Life Sci. 2019. DOI:https://doi.org/10.1007/s00018-019-03387-9
- Lando D. Asparagine hydroxylation of the HIF transactivation domain: a hypoxic switch. Science. 2002;295(5556):858–861.
- Ng KM, Lee YK, Chan YC, et al. Exogenous expression of HIF-1α promotes cardiac differentiation of embryonic stem cells. J Mol Cell Cardiol. 2010;48(6):1129–1137.
- Ryan HE. HIF-1alpha is required for solid tumor formation and embryonic vascularization. Embo J. 1998;17(11):3005–3015.
- Jiang BH, Agani F, Passaniti A, et al. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res. 1997;57(23):5328–5335.
- Zhong H, Agani F, Baccala AA, et al. Increased expression of hypoxia inducible factor-1alpha in rat and human prostate cancer. Cancer Res. 1998;58(23):5280–5284.
- Chen D, Li M, Luo J, et al. Direct interactions between HIF-1α and Mdm2 modulate p53 function. J Biol Chem. 2003. DOI:https://doi.org/10.1074/jbc.C200694200
- Greijer AE. The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. J Clin Pathol. 2004;57(10):1009–1014.
- Kothari S, Cizeau J, McMillan-Ward E, et al. BNIP3 plays a role in hypoxic cell death in human epithelial cells that is inhibited by growth factors EGF and IGF. Oncogene. 2003;22(30):4734–4744.
- Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. 1996;16(9):4604–4613.
- Melillo G, Musso T, Sica A, et al. A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter. J Exp Med. 1995;182(6):1683–1693.
- Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med. 2003. DOI:https://doi.org/10.1038/nm0603-677
- Takahashi Y, Takahashi S, Shiga Y, et al. Hypoxic induction of prolyl 4-hydroxylase α(I) in cultured cells. J Biol Chem. 2000;275(19):14139–14146.
- Nalbandian M, Takeda M. Lactate as a signaling molecule that regulates exercise-induced adaptations. Biology (Basel). 2016. DOI:https://doi.org/10.3390/biology5040038
- Wenger RH. Cellular adaptation to hypoxia: O2-sensing protein hydroxylases, hypoxia-inducible transcription factors, and O2-regulated gene expression. Faseb J. 2002;16(10):1151–1162.
- Semenza GL. Hif-1 and human disease: one highly involved factor. Genes Dev. 2000. DOI:https://doi.org/10.1101/gad.14.16.1983
- Werth N, Beerlage C, Rosenberger C, et al. Activation of hypoxia inducible factor 1 is a general phenomenon in infections with human pathogens. PLoS ONE. 2010;5(7):e11576.
- Morinet F, Parent M, Pillet S, et al. Hypoxia inducible factor one alpha and human viral pathogens. Curr Res Transl Med. 2017;65(1):7–9.
- Morinet F, Parent M, Bergeron C, et al. Oxygen and viruses: a breathing story. J Gen Virol. 2015;96(8):1979–1982.
- Morinet F, Casetti L, François JH, et al. Oxygen tension level and human viral infections. Virology. 2013;444(1–2):31–36.
- Hellwig-Bürgel T, Stiehl DP, Wagner AE, et al. Review: hypoxia-inducible factor-1 (HIF-1): a novel transcription factor in immune reactions. J Interferon Cytokine Res. 2005;25(6):297–310.
- Dos Santos SA, de Andrade DR Júnior. HIF–1alpha and infectious diseases: A new frontier for the development of new therapies. Rev Inst Med Trop Sao Paulo. 2017. DOI:https://doi.org/10.1590/S1678-9946201759092
- Kallio PJ, Pongratz I, Gradin K, et al. Activation of hypoxia-inducible factor 1 : posttranscriptional regulation and conformational change by recruitment of the Arnt transcription factor. Proc Natl Acad Sci U S A. 1997;94(11):5667–5672.
- Masson N, Willam C, Maxwell PH, et al. Independent function of two destruction domains in hypoxia-inducible factor-α chains activated by prolyl hydroxylation. Embo J. 2001;20(18):5197–5206.
- Hirota K, Semenza GL. Regulation of hypoxia-inducible factor 1 by prolyl and asparaginyl hydroxylases. Biochem Biophys Res Commun. 2005;338(1):610–616.
- Ivan M, Kondo K, Yang H, et al. HIFα targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science. 2001;292(5516):464–468.
- Huang LE, Arany Z, Livingston DM, et al. Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its α subunit. J Biol Chem. 1996;271(50):32253–32259.
- Palazon A, Goldrath AW, Nizet V, et al. HIF transcription factors, inflammation, and immunity. Immunity. 2014;41(4):518–528.
- Biron CA. Innate immunity: recognizing and responding to foreign invaders-no training needed. Viral Pathogenesis: Basics Syst Biol: Third Ed. 2016. DOI:https://doi.org/10.1016/B978-0-12-800964-2.00004-5
- Medzhitov R, Janeway CA. Innate immunity: the virtues of a nonclonal system of recognition. Cell. 1997;91(3):295–298.
- Kao RL, Browder W, Li C. Cellular cardiomyoplasty: what have we learned? Asian Cardiovasc Thorac Ann. 2009;17(1):89–101.
- Wang GL, Jiang BH, Semenza GL. Effect of protein kinase and phosphatase inhibitors on expression of hypoxia inducible factor 1. Biochem Biophys Res Commun. 1995;216(2):669–675.
- Zhang M, Wu Y, Wang M, et al. Genistein rescues hypoxia-induced pulmonary arterial hypertension through estrogen receptor and β-adrenoceptor signaling. J Nutr Biochem. 2018;58:110–118.
- Banerjee S, Li Y, Wang Z, et al. Multi-targeted therapy of cancer by genistein. Cancer Lett. 2008;269(2):226–242.
- Li S, Li J, Dai W, et al. Genistein suppresses aerobic glycolysis and induces hepatocellular carcinoma cell death. Br J Cancer. 2017;117(10):1518–1528.
- Nasimuzzaman M, Waris G, Mikolon D, et al. Hepatitis C virus stabilizes hypoxia-inducible factor 1α and stimulates the synthesis of vascular endothelial growth factor. J Virol. 2007;81(19):10249–10257.
- Chan DA, Sutphin PD, Denko NC, et al. Role of prolyl hydroxylation in oncogenically stabilized hypoxia-inducible factor-1α. J Biol Chem. 2002;277(42):40112–40117.
- Sodhi A, Montaner S, Miyazaki H, et al. MAPK and akt Act cooperatively but independently on hypoxia inducible factor-1α in rasV12 upregulation of VEGF. Biochem Biophys Res Commun. 2001;287(1):292–300.
- Zhong H, Chiles K, Feldser D, et al. Modulation of hypoxia-inducible factor 1α expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 2000;60(6):1541–1545.
- Cummins EP, Berra E, Comerford KM, et al. Prolyl hydroxylase-1 negatively regulates IκB kinase-β, giving insight into hypoxia-induced NFκB activity. Proc Natl Acad Sci U S A. 2006;103(48):18154–18159.
- Walmsley SR, Print C, Farahi N, et al. Hypoxia-induced neutrophil survival is mediated by HIF-1α-dependent NF-κB activity. J Exp Med. 2005;201(1):105–115.
- Abbas AK, L AH, P S. Cellular and molecular immunology, ninth edition. Cell Mol Immunol. 2018;Chapter 4, 57-95.
- Naldini A, Carraro F, Fleischmann WR, et al. Hypoxia Enhances the Antiviral Activity of Interferons. J Interferon Res. 1993;13(2):127–132.
- Netea MG, Schlitzer A, Placek K, et al. Innate and adaptive immune memory: an evolutionary continuum in the host’s response to pathogens. Cell Host Microbe. 2019;25(1):13–26.
- Ito T, Connett JM, Kunkel SL, et al. The linkage of innate and adaptive immune response during granulomatous development. Front Immunol. 2013;4. DOI:https://doi.org/10.3389/fimmu.2013.00010.
- Mancino A, Schioppa T, Larghi P, et al. Divergent effects of hypoxia on dendritic cell functions. Blood. 2008;112(9):3723–3734.
- Ricciardi A, Elia AR, Cappello P, et al. Transcriptome of hypoxic immature dendritic cells: modulation of chemokine/receptor expression. Mol Cancer Res. 2008;6(2):175–185.
- Lappas CM, Rieger JM, Linden J. A 2A adenosine receptor induction inhibits IFN-γ production in murine CD4 + T cells. J Immunol. 2005;174(2):1073–1080.
- Lukashev D, Klebanov B, Kojima H, et al. Cutting edge: hypoxia-inducible factor 1α and Its activation-inducible short isoform i.1 negatively regulate functions of CD4+ and CD8+ T lymphocytes. J Immunol. 2006;177(8):4962–4965.
- Sitkovsky M, Lukashev D. Regulation of immune cells by local-tissue oxygen tension: HIF1α and adenosine receptors. Nat Rev Immunol. 2005;5(9):712–721.
- Dang EV, Barbi J, Yang HY, et al. Control of TH17/Treg balance by hypoxia-inducible factor 1. Cell. 2011;146(5):772–784.
- Doedens AL, Phan AT, Stradner MH, et al. Hypoxia-inducible factors enhance the effector responses of CD8+ T cells to persistent antigen. Nat Immunol. 2013;14(11):1173–1182.
- Yang A, Farmer E, Wu TC, et al. Perspectives for therapeutic HPV vaccine development. J Biomed Sci. 2016;23(1). DOI:https://doi.org/10.1186/s12929-016-0293-9
- Birner P, Schindl M, Obermair A, et al. Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res. 2000b;60(17):4693–4696.
- Li G, He L, Zhang E, et al. Overexpression of human papillomavirus (HPV) type 16 oncoproteins promotes angiogenesis via enhancing HIF-1α and VEGF expression in non-small cell lung cancer cells. Cancer Lett. 2011;311(2):160–170.
- Tang X, Zhang Q, Nishitani J, et al. Overexpression of human papillomavirus type 16 oncoproteins enhances hypoxia-inducible factor 1 protein accumulation and vascular endothelial growth factor expression in human cervical carcinoma cells. Clin Cancer Res. 2007;13(9):2568–2576.
- Nakamura M, Bodily JM, Beglin M, et al. Hypoxia-specific stabilization of HIF-1alpha by human papillomaviruses. Virology. 2009;387(2):442–448.
- Cohen JI. Optimal treatment for chronic active Epstein-Barr virus disease: editorial. Pediatr Transplant. 2009;13(4):393–396.
- Kondo S, Seo SY, Yoshizaki T, et al. EBV latent membrane protein 1 up-regulates hypoxia-inducible factor 1α through Siah1-mediated down-regulation of prolyl hydroxylases 1 and 3 in nasopharyngeal epithelial cells. Cancer Res. 2006. DOI:https://doi.org/10.1158/0008-5472.CAN-06-1679
- Sung -W-W, Chu Y-C, Chen P-R, et al. Positive regulation of HIF-1A expression by EBV oncoprotein LMP1 in nasopharyngeal carcinoma cells. Cancer Lett. 2016;382(1):21–31.
- Wakisaka N, Kondo S, Yoshizaki T, et al. Epstein-Barr Virus latent membrane protein 1 induces synthesis of hypoxia-inducible factor 1α. Mol Cell Biol. 2004;24(12):5223–5234.
- Jiang J-H, Wang N, Li A, et al. Hypoxia can contribute to the induction of the Epstein-Barr virus (EBV) lytic cycle. J Clin Virol. 2006;37(2):98–103.
- Kraus RJ, Yu X, Cordes B, et al. Hypoxia-inducible factor-1α plays roles in Epstein-Barr virus’s natural life cycle and tumorigenesis by inducing lytic infection through direct binding to the immediate-early BZLF1 gene promoter. PLoS Pathog. 2017;13(6):e1006404.
- Mesri EA, Cesarman E, Boshoff C. Kaposi’s sarcoma and its associated herpesvirus. Nat Rev Cancer. 2010;10(10):707–719.
- Carroll PA, Kenerson HL, Yeung RS, et al. Latent kaposi’s sarcoma-associated Herpesvirus infection of endothelial cells activates hypoxia-induced factors. J Virol. 2006;80(21):10802–10812.
- Shin YC, Joo CH, Gack MU, et al. Kaposi’s sarcoma-associated herpesvirus viral IFN regulatory factor 3 stabilizes hypoxia-inducible factor-1α to induce vascular endothelial growth factor expression. Cancer Res. 2008;68(6):1751–1759.
- DiMaio TA, Lagunoff M. KSHV induction of angiogenic and lymphangiogenic phenotypes. Front Microbiol. 2012;3. DOI:https://doi.org/10.3389/fmicb.2012.00102.
- Purushothaman P, Uppal T, Sarkar R, et al. KSHV-mediated angiogenesis in tumor progression. Viruses. 2016;8(7):198.
- Ma T, Patel H, Babapoor-Farrokhran S, et al. KSHV induces aerobic glycolysis and angiogenesis through HIF-1-dependent upregulation of pyruvate kinase 2 in Kaposi’s sarcoma. Angiogenesis. 2015;18(4):477–488.
- Cai Q, Lan K, Verma SC, et al. Kaposi’s sarcoma-associated Herpesvirus latent protein LANA interacts with HIF-1α to upregulate RTA expression during hypoxia: latency control under low oxygen conditions. J Virol. 2006;80(16):7965–7975.
- Davis DA, Rinderknecht AS, Paul Zoeteweij J, et al. Hypoxia induces lytic replication of Kaposi sarcoma-associated herpesvirus. Blood. 2001;97(10):3244–3250.
- Zhang L, Zhu C, Guo Y, et al. Inhibition of KAP1 enhances hypoxia-induced kaposi’s sarcoma-associated Herpesvirus reactivation through RBP-J. J Virol. 2014. DOI:https://doi.org/10.1128/jvi.00283-14
- Singh RK, Lang F, Pei Y, et al. Metabolic reprogramming of Kaposi’s sarcoma associated herpes virus infected B-cells in hypoxia. PLoS Pathog. 2018;14(5):e1007062.
- Griffiths P, Baraniak I, Reeves M. The pathogenesis of human cytomegalovirus. J Pathol. 2015;235(2):288–297.
- McFarlane S, Nicholl MJ, Sutherland JS, et al. Interaction of the human cytomegalovirus particle with the host cell induces hypoxia-inducible factor 1 alpha. Virology. 2011;414(1):83–90.
- de Wit RH, Mujic-Delic A, van Senten JR, et al. Human cytomegalovirus encoded chemokine receptor US28 activates the HIF-1α/PKM2 axis in glioblastoma cells. Oncotarget. 2016;7(42):67966–67985.
- Rao P, Suvas S. Development of inflammatory hypoxia and prevalence of glycolytic metabolism in progressing herpes stromal keratitis lesions. J Immunol. 2019;202(2):514–526.
- Pietropaolo V, Prezioso C, Bagnato F, et al. John Cunningham virus: an overview on biology and disease of the etiological agent of the progressive multifocal leukoencephalopathy. New Microbiol. 2018;41(3):179–186.
- Piña-Oviedo S, Khalili K, Del Valle L. Hypoxia inducible factor-1 alpha activation of the JCV promoter: role in the pathogenesis of Progressive Multifocal Leukoencephalopathy. Acta Neuropathol. 2009;118(2):235–247.
- Chan ST, Ou JHJ. Hepatitis C virus-induced autophagy and host innate immune response. Viruses. 2017. DOI:https://doi.org/10.3390/v9080224
- Vassilaki N, Kalliampakou KI, Kotta-Loizou I, et al. Low oxygen tension enhances hepatitis C virus replication. J Virol. 2013;87(5):2935–2948.
- Zhu C, Liu X, Wang S, et al. Hepatitis C virus core protein induces hypoxia-inducible factor 1α-mediated vascular endothelial growth factor expression in Huh7.5.1 cells. Mol Med Rep. 2014. DOI:https://doi.org/10.3892/mmr.2014.2039
- Ripoli M, D’Aprile A, Quarato G, et al. Hepatitis C virus-linked mitochondrial dysfunction promotes hypoxia-inducible factor 1α-mediated glycolytic adaptation. J Virol. 2010;84(1):647–660.
- Nimgaonkar I, Ding Q, Schwartz RE, et al. Hepatitis e virus: advances and challenges. Nat Rev Gastroenterol Hepatol. 2018. DOI:https://doi.org/10.1038/nrgastro.2017.150
- Moin SM, Chandra V, Arya R, et al. The hepatitis E virus ORF3 protein stabilizes HIF-1α and enhances HIF-1-mediated transcriptional activity through p300/CBP. Cell Microbiol. 2009;11(9):1409–1421.
- Uno N, Ross TM. Dengue virus and the host innate immune response. Emerging Microbes Infect. 2018;7(1):1–11.
- Frakolaki E, Kaimou P, Moraiti M, et al. The role of tissue oxygen tension in Dengue Virus replication. Cells. 2018;7(12):241.
- Afsar B, Kanbay M, Afsar RE. Hypoxia inducible factor-1 protects against COVID-19: a hypothesis. Med Hypotheses. 2020;143:109857.
- Hamming I, Timens W, Bulthuis MLC, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631–637.
- Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565–574.
- Zhang R, Wu Y, Zhao M, et al. Role of HIF-1α in the regulation ACE and ACE2 expression in hypoxic human pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 2009;297(4):L631-L640.
- Glinsky GV. Tripartite combination of candidate pandemic mitigation agents: vitamin D, Quercetin, and Estradiol Manifest properties of medicinal agents for targeted mitigation of the COVID-19 pandemic defined by genomics-guided tracing of SARS-CoV-2 targets in human. Biomedicines. 2020. DOI:https://doi.org/10.3390/BIOMEDICINES8050129
- Arias-Reyes C, Zubieta-DeUrioste N, Poma-Machicao L, et al. Does the pathogenesis of SARS-CoV-2 virus decrease at high-altitude? Respir Physiol Neurobiol. 2020;277:103443.
- Shao W, Li X, Goraya MU, et al. Evolution of influenza a virus by mutation and re-assortment. Int J Mol Sci. 2017;18(8):1650.
- Ren L, Zhang W, Han P, et al. Influenza A virus (H1N1) triggers a hypoxic response by stabilizing hypoxia-inducible factor-1α via inhibition of proteasome. Virology. 2019;530:51–58.
- Guo X, Zhu Z, Zhang W, et al. Nuclear translocation of HIF-1α induced by influenza A (H1N1) infection is critical to the production of proinflammatory cytokines. Emerging Microbes Infect. 2017;6(1):1–8.
- Zhao C, Chen J, Cheng L, et al. Deficiency of HIF-1α enhances influenza A virus replication by promoting autophagy in alveolar type II epithelial cells. Emerging Microbes Infect. 2020;9(1):691–706.
- Bohmwald K, Espinoza JA, Rey-Jurado E, et al. Human respiratory Syncytial Virus: infection and pathology. Semin Respir Crit Care Med. 2016;37(4):522–537.
- Haeberle HA, Dürrstein C, Rosenberger P, et al. Oxygen-independent stabilization of hypoxia inducible factor (HIF)-1 during RSV infection. PLoS ONE. 2008. DOI:https://doi.org/10.1371/journal.pone.0003352
- Kilani MM, Mohammed KA, Nasreen N, et al. RSV causes HIF-1α stabilization via NO release in primary bronchial epithelial cells. Inflammation. 2004;28(5):245–251.
- Ganar K, Das M, Sinha S, et al. Newcastle disease virus: current status and our understanding. Virus Res. 2014;184:71–81.
- Etriwati RD, Setiyaningsih S, Setiyaningsih S. Pathology and immunohistochemistry study of Newcastle disease field case in chicken in Indonesia. Vet World. 2017;10(9):1066–1071.
- Abd-Aziz N, Stanbridge EJ, Shafee N. Newcastle disease virus degrades HIF-1α through proteasomal pathways independent of VHL and p53. J Gen Virol. 2016;97(12):3174–3182.
- McDonald PC, Dedhar S. Carbonic anhydrase IX (CAIX) as a mediator of hypoxia-induced stress response in cancer cells. Subcell Biochem. 2014. DOI:https://doi.org/10.1007/978-94-007-7359-2_13
- Rozo-Lopez P, Drolet BS, Londoño-Renteria B. Vesicular stomatitis virus transmission: a comparison of incriminated vectors. Insects. 2018;9(4):190.
- Hwang IIL, Watson IR, Der SD, et al. Loss of VHL confers hypoxia-inducible factor (HIF)-dependent resistance to vesicular Stomatitis Virus: role of HIF in antiviral response. J Virol. 2006;80(21):10712–10723.
- Norman KL, Hirasawa K, Yang AD, et al. Reovirus oncolysis: the Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection. Proc Natl Acad Sci U S A. 2004;101(30):11099–11104.
- Hotani T, Tachibana M, Mizuguchi H, et al. Reovirus double-stranded RNA genomes and polyI:C induce down-regulation of hypoxia-inducible factor 1α. Biochem Biophys Res Commun. 2015;460(4):1041–1046.
- Hotani T, Mizuguchi H, Sakurai F. Systemically administered Reovirus-induced downregulation of hypoxia inducible factor-1α in subcutaneous tumors. Mol Ther Oncolytics. 2019;12:162–172. .
- Karayiannis P. Hepatitis B virus: virology, molecular biology, life cycle and intrahepatic spread. Hepatol Int. 2017. DOI:https://doi.org/10.1007/s12072-017-9829-7
- Moon EJ, Jeong CH, Jeong JW, et al. Hepatitis B virus X protein induces angiogenesis by stabilizing hypoxia-inducible factor-1alpha. FASEB J : Off Publ Fed Am Soc Exp Biol. 2004;18(2):1–16.
- Slagle BL, Bouchard MJ. Hepatitis B virus X and regulation of viral gene expression. Cold Spring Harb Perspect Med. 2016;6(3):a021402.
- Han HK, Han CY, Cheon EP, et al. Role of hypoxia-inducible factor-α in hepatitis-B-virus X protein-mediated MDR1 activation. Biochem Biophys Res Commun. 2007;357(2):567–573.
- Levy JA. Pathogenesis of human immunodeficiency virus infection. Microbiol Rev. 1993;57(1):183–289.
- Deshmane SL, Amini S, Sen S, et al. Regulation of the HIV-1 promoter by HIF-1 and Vpr proteins. Virol J. 2011;8(1):477.
- Deshmane SL, Mukerjee R, Fan S, et al. Activation of the oxidative stress pathway by HIV-1 Vpr leads to induction of hypoxia-inducible factor 1α expression. J Biol Chem. 2009;284(17):11364–11373.
- Duette G, Pereyra Gerber P, Rubione J, et al. Induction of HIF-1α by HIV-1 infection in CD4 + T cells promotes viral replication and drives extracellular vesicle-mediated inflammation. MBio. 2018;9(5). DOI:https://doi.org/10.1128/mBio.00757-18
- Fallah J, Rini BI. HIF inhibitors: status of current clinical development. Curr Oncol Rep. 2019;21(1). DOI:https://doi.org/10.1007/s11912-019-0752-z
- Lee JW, Ko J, Ju C, et al. Hypoxia signaling in human diseases and therapeutic targets. Exp Mol Med. 2019. DOI:https://doi.org/10.1038/s12276-019-0235-1
- Eltzschig HK, Bratton DL, Colgan SP. Targeting hypoxia signalling for the treatment of ischaemic and inflammatory diseases. Nat Rev Drug Discov. 2014. DOI:https://doi.org/10.1038/nrd4422
- Semenza GL. Hypoxia-inducible factor 1 and cardiovascular disease. Annu Rev Physiol. 2014;76(1):39–56.
- Sano M, Minamino T, Toko H, et al. p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature. 2007;446(7134):444–448.
- Semenza GL. Regulation of metabolism by hypoxia-inducible factor 1. Cold Spring Harb Symp Quant Biol. 2011;76:347–353.
- Wei H, Bedja D, Koitabashi N, et al. Endothelial expression of hypoxia-inducible factor 1 protects the murine heart and aorta from pressure overload by suppression of TGF- signaling. Proc Natl Acad Sci U S A. 2012;109(14):E841-E850.
- Hölscher M, Schäfer K, Krull S, et al. Unfavourable consequences of chronic cardiac HIF-1α stabilization. Cardiovasc Res. 2012;94(1):77–86.
- Haase VH. HIF-prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism. Hemodialysis Int. 2017;21:S110-S124. .
- Rapa SF, Di Iorio BR, Campiglia P, et al. Inflammation and oxidative stress in chronic kidney disease—potential therapeutic role of minerals, vitamins and plant-derived metabolites. Int J Mol Sci. 2020. DOI:https://doi.org/10.3390/ijms21010263
- Tanaka T, Eckardt KU. HIF Activation Against CVD in CKD: novel Treatment Opportunities. Semin Nephrol. 2018;38(3):267–276.
- Jelkmann W. Regulation of erythropoietin production. J Physiol. 2011;589(6):1251–1258.
- Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3(10):721–732.
- Laughner E, Taghavi P, Chiles K, et al. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1α (HIF-1α) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol. 2001;21(12):3995–4004.
- Ravi R, Mookerjee B, Bhujwalla ZM, et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia- inducible factor 1α. Genes Dev. 2000. DOI:https://doi.org/10.1101/gad.14.1.34
- Maxwell PH, Wlesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;117(10):1518–1528.
- Beasley NJP, Leek R, Alam M, et al. Hypoxia-inducible factors HIF-1α and HIF-2α in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients. Cancer Res. 2002;62(9):2493–2497.
- Volm M, Koomägi R. Hypoxia-inducible factor (HIF-1) and its relationship to apoptosis and proliferation in lung cancer. Anticancer Res. 2000;20(3A):1527–1533.
- Koukourakis MI, Giatromanolaki A, Sivridis E, et al. Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2002;53(5):1192–1202.
- Giatromanolaki A, Koukourakis MI, Sivridis E, et al. Relation of hypoxia inducible factor 1α and 2α in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer. 2001;85(6):881–890.
- Birner P, Schindl M, Obermair A, et al. Overexpression of hypoxia-inducible factor 1α is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res. 2000a;60(17):4693–4696.
- Schindl M, Schoppmann SF, Samonigg H, et al. Overexpression of hypoxia-inducible factor 1α is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res. 2002;8(6):1831–1837.
- Sivridis E, Giatromanolaki A, Gatter KC, et al. Association of hypoxia-inducible factors 1α and 2α with activated angiogenic pathways and prognosis in patients with endometrial carcinoma. Cancer. 2002;95(5):1055–1063.
- Aebersold DM, Burri P, Beer KT, et al. Expression of hypoxia-inducible factor-1α: A novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res. 2001;61(7):2911–2916.
- Birner P, Schindl M, Obermair A, et al. Expression of hypoxia-inducible factor 1α in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res. 2001;7(6):1661–1668.
- Choudhry H, Albukhari A, Morotti M, et al. Tumor hypoxia induces nuclear paraspeckle formation through HIF-2α dependent transcriptional activation of NEAT1 leading to cancer cell survival. Oncogene. 2015. DOI:https://doi.org/10.1038/onc.2014.378
- Kaidi A, Qualtrough D, Williams AC, et al. Direct transcriptional up-regulation of cyclooxygenase-2 by hypoxia-inducible factor (HIF)-1 promotes colorectal tumor cell survival and enhances HIF-1 transcriptional activity during hypoxia. Cancer Res. 2006;66(13):6683–6691.
- Yoo Y-G, Christensen J, Huang LE. HIF-1α confers aggressive malignant traits on human tumor cells independent of its canonical transcriptional function. Cancer Res. 2011;71(4):1244–1252.
- Corzo CA, Condamine T, Lu L, et al. HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med. 2010;207(11):2439–2453.
- Zhao T, Ren H, Jia L, et al. Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma. Oncotarget. 2015. DOI:https://doi.org/10.18632/oncotarget.2948
- Pore N, Gupta AK, Cerniglia GJ, et al. Nelfinavir down-regulates hypoxia-inducible factor 1α and VEGF expression and increases tumor oxygenation: implications for radiotherapy. Cancer Res. 2006;66(18):9252–9259.
- Cramer T, Yamanishi Y, Clausen BE, et al. HIF-1α is essential for myeloid cell-mediated inflammation. Cell. 2003;112(5):645–657.
- Giaccia A, Siim BG, Johnson RS. HIF-1 as a target for drug development. Nat Rev Drug Discov. 2003;2(10):803–811.
- Hu D, Linders A, Yamak A, et al. Metabolic maturation of human pluripotent stem cellderived cardiomyocytes by inhibition of HIF1α and LDHA. Circ Res. 2018. DOI:https://doi.org/10.1161/CIRCRESAHA.118.313249
- Huang H, Fan Y, Gao Z, et al. HIF-1α contributes to Ang II-induced inflammatory cytokine production in podocytes. BMC Pharmacol Toxicol. 2019;20(1). DOI:https://doi.org/10.1186/s40360-019-0340-8
- Yu T, Tang B, Sun X. Development of inhibitors targeting hypoxia-inducible factor 1 and 2 for cancer therapy. Yonsei Med J. 2017;58(3):489.
- Okumura CYM, Hollands A, Tran DN, et al. A new pharmacological agent (AKB-4924) stabilizes hypoxia inducible factor-1 (HIF-1) and increases skin innate defenses against bacterial infection. J Mol Med. 2012;90(9):1079–1089.